For instance, a previous study demonstrated that the combination of CD44-targeted NIR-PIT and either immune checkpoint blockade or Treg-targeted NIR-PIT showed inconsistent therapeutic efficacy among these three tumor models [13,14,24]. This evidence concerns the gene CD44 and neoplasm.